Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Chubb
Medtronic
Covington
Queensland Health
Cerilliant
US Department of Justice
Federal Trade Commission
Harvard Business School

Generated: September 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 009190

« Back to Dashboard

NDA 009190 describes LIPIODOL, which is a drug marketed by Guerbet and is included in one NDA. It is available from one supplier. Additional details are available on the LIPIODOL profile page.

The generic ingredient in LIPIODOL is ethiodized oil. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ethiodized oil profile page.
Summary for 009190
Tradename:LIPIODOL
Applicant:Guerbet
Ingredient:ethiodized oil
Patents:0
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 009190
Generic Entry Date for 009190*:
Constraining patent/regulatory exclusivity:
SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC)
Dosage:
OIL;INTRALYMPHATIC, INTRAUTERINE

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Medical Subject Heading (MeSH) Categories for 009190
Suppliers and Packaging for NDA: 009190
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LIPIODOL ethiodized oil OIL;INTRALYMPHATIC, INTRAUTERINE 009190 NDA Guerbet LLC 67684-1901 67684-1901-1 1 AMPULE in 1 CARTON (67684-1901-1) > 10 mL in 1 AMPULE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:OIL;INTRALYMPHATIC, INTRAUTERINEStrengthEQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 4, 2021
Regulatory Exclusivity Use:SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC)

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Queensland Health
AstraZeneca
Chubb
Cerilliant
Citi
Chinese Patent Office
UBS
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.